Time filter

Source Type

Patent
Taiho Pharmaceutical Co | Date: 2016-10-18

An acetic acid ester compound represented by the following formula (I) or a salt thereof, wherein R represents optionally substituted deuterated lower alkyl, is disclosed.


Patent
Taiho Pharmaceutical Co | Date: 2016-10-19

Provided is a preventive and/or therapeutic agent for immune diseases containing a compound having a BTK inhibitory activity or a salt thereof, as an active ingredient. A preventive and/or therapeutic agent of immune diseases, comprising a compound represented by Formula (I), where R_(1 )to R_(3), W, X, Y, Z, and n represent those as defined in the specification, or a salt thereof, as an active ingredient.


Patent
Taiho Pharmaceutical Co | Date: 2016-05-16

Problem to Be Solved by the Invention: To providing a method for ameliorating DHIC. Means for Solving the Problem: This invention is directed to a treating method for DHIC, comprising the step of administering a therapeutically effective amount of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof.


Patent
Taiho Pharmaceutical Co | Date: 2016-10-19

Provided is a salt having a high selectivity to BTK and is useful as a drug ingredient for a pharmaceutical product. It has been found that fumarate of Compound A is free of a characteristic of channel hydrate and is stable and excellent in absorptive property, compared to Compound A or other salts thereof.


In order to provide a novel cancer treatment method using a FTDTPI combination drug that exhibits markedly excellent anti-tumor effects with fewer side effects, the present invention provides an anti-tumor agent characterized in that the FTDTPI combination drug and an anti-tumor platinum complex are administered in combination.


Patent
Taiho Pharmaceutical Co | Date: 2017-02-08

In order to provide a novel cancer treatment method using a FTDTPI combination drug that exhibits markedly excellent anti-tumor effects with fewer side effects, the present invention provides an anti-tumor agent characterized in that the FTDTPI combination drug and a taxane compound are administered in combination.


Patent
Taiho Pharmaceutical Co | Date: 2017-01-11

Provided is a salt having a high selectivity to BTK and is useful as a drug ingredient for a pharmaceutical product. It has been found that fumarate of Compound A is free of a characteristic of channel hydrate and is stable and excellent in absorptive property, compared to Compound A or other salts thereof.


Patent
Taiho Pharmaceutical Co | Date: 2017-01-25

Provided is a preventive and/or therapeutic agent for immune diseases containing a compound having a BTK inhibitory activity or a salt thereof, as an active ingredient. A preventive and/or therapeutic agent of immune diseases, comprising a compound represented by Formula (I), where R_(1) to R_(3), W, X, Y, Z, and n represent those as defined in the specification, or a salt thereof, as an active ingredient.


Patent
Taiho Pharmaceutical Co | Date: 2017-04-05

To provide a compound having an inhibitory activity for an androgen receptor. A tetrahydropyridopyrimidine compound represented by the following general formula (I) or a pharmaceutically acceptable thereof (in the formula, X and R are as defined in the specification).


Ueno H.,Taiho Pharmaceutical Co
Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2013

The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival. The participants were chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m(2) on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle), or gemcitabine plus S-1 (gemcitabine 1,000 mg/m(2) on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle). In the total of 834 enrolled patients, median overall survival was 8.8 months in the gemcitabine group, 9.7 months in the S-1 group, and 10.1 months in the gemcitabine plus S-1 group. The noninferiority of S-1 to gemcitabine was demonstrated (hazard ratio, 0.96; 97.5% CI, 0.78 to 1.18; P < .001 for noninferiority), whereas the superiority of gemcitabine plus S-1 was not (hazard ratio, 0.88; 97.5% CI, 0.71 to 1.08; P = .15). All treatments were generally well tolerated, although hematologic and GI toxicities were more severe in the gemcitabine plus S-1 group than in the gemcitabine group. Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer.

Loading Taiho Pharmaceutical Co collaborators
Loading Taiho Pharmaceutical Co collaborators